术前MRI对HER2阳性及激素受体阴性乳腺癌患者生存结局的影响
本回顾性研究纳入2007年1月至2016年12月诊断的1094例HER2阳性、激素受体阴性浸润性导管癌女性,采用倾向性评分匹配比较术前MRI组与未MRI组的无复发生存期和总生存期。结果显示术前MRI与总复发、局部区域复发、对侧乳腺复发、远处复发及总生存期改善均无显著关联。
要点
- 在倾向性评分匹配集中,术前MRI与总复发风险无显著关联(HR 0.69,95%CI 0.47–1.02,P=.06)。
- 术前MRI与总生存期改善无显著关联(HR 0.63,95%CI 0.39–1.00,P=.05)。
- 多变量分析中术前MRI与无复发生存期(HR 0.89,95%CI 0.67–1.19,P=.44)及总生存期(HR 0.73,95%CI 0.48–1.10,P=.14)改善均无显著关联。
核心结论
- 术前MRI未改善HER2阳性及激素受体阴性乳腺癌患者的无复发生存期或总生存期。
研究设计与样本
- 回顾性研究纳入2007年1月至2016年12月诊断的HER2阳性、激素受体阴性浸润性导管癌女性1094例(中位年龄52岁,年龄范围24–91岁),基于19项临床病理协变量进行倾向性评分匹配,比较MRI组与未MRI组。
诊断标准与关键数值
- 倾向性评分匹配集中,术前MRI与总复发无显著关联(HR 0.69,95%CI 0.47–1.02,P=.06)。
- 倾向性评分匹配集中,术前MRI与局部区域复发无显著关联(HR 0.94,95%CI 0.52–1.70,P=.84)。
- 倾向性评分匹配集中,术前MRI与对侧乳腺复发无显著关联(HR 0.55,95%CI 0.24–1.25,P=.15)。
- 倾向性评分匹配集中,术前MRI与远处复发无显著关联(HR 0.56,95%CI 0.31–1.03,P=.06)。
- 倾向性评分匹配集中,术前MRI与总生存期改善无显著关联(HR 0.63,95%CI 0.39–1.00,P=.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Little is known regarding the impact of preoperative breast MRI on the long-term outcomes of patients with breast cancer that is human epidermal growth factor receptor 2 (HER2) positive and hormone receptor negative. Purpose To evaluate the impact of preoperative breast MRI on recurrence-free survival (RFS) and overall survival (OS) in patients with HER2-positive and hormone receptor-negative breast cancer by using propensity score matching. Materials and Methods This retrospective study included women diagnosed with HER2-positive and hormone receptor-negative invasive ductal carcinoma between January 2007 and December 2016. Patients who underwent preoperative MRI (the MRI group) were matched with those who did not (the no-MRI group) using propensity score matching based on 19 clinical-pathologic covariates. RFS and OS were compared using Kaplan-Meier estimates, Cox proportional hazards models, and inverse probability weighting. Results Among 1094 women (median age, 52 years; age range, 24-91 years), 47.81% (523 of 1094) underwent preoperative MRI. The rates of total recurrence and death were 14.3% (75 of 523) and 7.07% (37 of 523) in the MRI group, respectively, compared with 16.5% (94 of 571) and 13.1% (75 of 571) in the no-MRI group. In the propensity score-matched set, preoperative MRI was not associated with total recurrence (hazard ratio [HR], 0.69; 95% CI: 0.47, 1.02; P = .06), local-regional recurrence (HR, 0.94; 95% CI: 0.52, 1.70; P = .84), contralateral breast recurrence (HR, 0.55; 95% CI: 0.24, 1.25; P = .15), or distant recurrence (HR, 0.56; 95% CI: 0.31, 1.03; P = .06). OS was not higher with preoperative MRI (HR, 0.63; 95% CI: 0.39, 1.00; P = .05). At multivariable analysis, preoperative MRI was not associated with improved RFS (HR, 0.89; 95% CI: 0.67, 1.19; P = .44) or OS (HR, 0.73; 95% CI: 0.48, 1.10; P = .14). Conclusion Preoperative MRI did not improve RFS or OS in patients with HER2-positive and hormone receptor-negative breast cancer. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Imbriaco and Ponsiglione in this issue.
引用
- Kim HJ, Choi WJ, Eom HJ, et al. Impact of Preoperative MRI on Survival Outcomes in Patients with HER2-positive and Hormone Receptor-negative Breast Cancer. Radiology. 2025. PMID: 40298601. doi:10.1148/radiol.242712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。